Copyright Reports & Markets. All rights reserved.

Global Immuno-oncology Therapy Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Immuno-oncology Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Monoclonal Antibodies
    • 1.2.3 Immune Checkpoint Inhibitors
    • 1.2.4 Immune System Modulators
    • 1.2.5 Cancer Vaccines
    • 1.2.6 Others
  • 1.3 Market by Application
    • 1.3.1 Global Immuno-oncology Therapy Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospitals
    • 1.3.3 Ambulatory Surgical Center
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Immuno-oncology Therapy Market Perspective (2016-2027)
  • 2.2 Immuno-oncology Therapy Growth Trends by Regions
    • 2.2.1 Immuno-oncology Therapy Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Immuno-oncology Therapy Historic Market Share by Regions (2016-2021)
    • 2.2.3 Immuno-oncology Therapy Forecasted Market Size by Regions (2022-2027)
  • 2.3 Immuno-oncology Therapy Industry Dynamic
    • 2.3.1 Immuno-oncology Therapy Market Trends
    • 2.3.2 Immuno-oncology Therapy Market Drivers
    • 2.3.3 Immuno-oncology Therapy Market Challenges
    • 2.3.4 Immuno-oncology Therapy Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Immuno-oncology Therapy Players by Revenue
    • 3.1.1 Global Top Immuno-oncology Therapy Players by Revenue (2016-2021)
    • 3.1.2 Global Immuno-oncology Therapy Revenue Market Share by Players (2016-2021)
  • 3.2 Global Immuno-oncology Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Immuno-oncology Therapy Revenue
  • 3.4 Global Immuno-oncology Therapy Market Concentration Ratio
    • 3.4.1 Global Immuno-oncology Therapy Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Therapy Revenue in 2020
  • 3.5 Immuno-oncology Therapy Key Players Head office and Area Served
  • 3.6 Key Players Immuno-oncology Therapy Product Solution and Service
  • 3.7 Date of Enter into Immuno-oncology Therapy Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Immuno-oncology Therapy Breakdown Data by Type

  • 4.1 Global Immuno-oncology Therapy Historic Market Size by Type (2016-2021)
  • 4.2 Global Immuno-oncology Therapy Forecasted Market Size by Type (2022-2027)

5 Immuno-oncology Therapy Breakdown Data by Application

  • 5.1 Global Immuno-oncology Therapy Historic Market Size by Application (2016-2021)
  • 5.2 Global Immuno-oncology Therapy Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Immuno-oncology Therapy Market Size (2016-2027)
  • 6.2 North America Immuno-oncology Therapy Market Size by Type
    • 6.2.1 North America Immuno-oncology Therapy Market Size by Type (2016-2021)
    • 6.2.2 North America Immuno-oncology Therapy Market Size by Type (2022-2027)
    • 6.2.3 North America Immuno-oncology Therapy Market Size by Type (2016-2027)
  • 6.3 North America Immuno-oncology Therapy Market Size by Application
    • 6.3.1 North America Immuno-oncology Therapy Market Size by Application (2016-2021)
    • 6.3.2 North America Immuno-oncology Therapy Market Size by Application (2022-2027)
    • 6.3.3 North America Immuno-oncology Therapy Market Size by Application (2016-2027)
  • 6.4 North America Immuno-oncology Therapy Market Size by Country
    • 6.4.1 North America Immuno-oncology Therapy Market Size by Country (2016-2021)
    • 6.4.2 North America Immuno-oncology Therapy Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Immuno-oncology Therapy Market Size (2016-2027)
  • 7.2 Europe Immuno-oncology Therapy Market Size by Type
    • 7.2.1 Europe Immuno-oncology Therapy Market Size by Type (2016-2021)
    • 7.2.2 Europe Immuno-oncology Therapy Market Size by Type (2022-2027)
    • 7.2.3 Europe Immuno-oncology Therapy Market Size by Type (2016-2027)
  • 7.3 Europe Immuno-oncology Therapy Market Size by Application
    • 7.3.1 Europe Immuno-oncology Therapy Market Size by Application (2016-2021)
    • 7.3.2 Europe Immuno-oncology Therapy Market Size by Application (2022-2027)
    • 7.3.3 Europe Immuno-oncology Therapy Market Size by Application (2016-2027)
  • 7.4 Europe Immuno-oncology Therapy Market Size by Country
    • 7.4.1 Europe Immuno-oncology Therapy Market Size by Country (2016-2021)
    • 7.4.2 Europe Immuno-oncology Therapy Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Immuno-oncology Therapy Market Size (2016-2027)
  • 8.2 Asia-Pacific Immuno-oncology Therapy Market Size by Type
    • 8.2.1 Asia-Pacific Immuno-oncology Therapy Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Immuno-oncology Therapy Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Immuno-oncology Therapy Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Immuno-oncology Therapy Market Size by Application
    • 8.3.1 Asia-Pacific Immuno-oncology Therapy Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Immuno-oncology Therapy Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Immuno-oncology Therapy Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Immuno-oncology Therapy Market Size by Region
    • 8.4.1 Asia-Pacific Immuno-oncology Therapy Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Immuno-oncology Therapy Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Immuno-oncology Therapy Market Size (2016-2027)
  • 9.2 Latin America Immuno-oncology Therapy Market Size by Type
    • 9.2.1 Latin America Immuno-oncology Therapy Market Size by Type (2016-2021)
    • 9.2.2 Latin America Immuno-oncology Therapy Market Size by Type (2022-2027)
    • 9.2.3 Latin America Immuno-oncology Therapy Market Size by Type (2016-2027)
  • 9.3 Latin America Immuno-oncology Therapy Market Size by Application
    • 9.3.1 Latin America Immuno-oncology Therapy Market Size by Application (2016-2021)
    • 9.3.2 Latin America Immuno-oncology Therapy Market Size by Application (2022-2027)
    • 9.3.3 Latin America Immuno-oncology Therapy Market Size by Application (2016-2027)
  • 9.4 Latin America Immuno-oncology Therapy Market Size by Country
    • 9.4.1 Latin America Immuno-oncology Therapy Market Size by Country (2016-2021)
    • 9.4.2 Latin America Immuno-oncology Therapy Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Immuno-oncology Therapy Market Size (2016-2027)
  • 10.2 Middle East & Africa Immuno-oncology Therapy Market Size by Type
    • 10.2.1 Middle East & Africa Immuno-oncology Therapy Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Immuno-oncology Therapy Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Immuno-oncology Therapy Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Immuno-oncology Therapy Market Size by Application
    • 10.3.1 Middle East & Africa Immuno-oncology Therapy Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Immuno-oncology Therapy Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Immuno-oncology Therapy Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Immuno-oncology Therapy Market Size by Country
    • 10.4.1 Middle East & Africa Immuno-oncology Therapy Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Immuno-oncology Therapy Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Amgen
    • 11.1.1 Amgen Company Details
    • 11.1.2 Amgen Business Overview
    • 11.1.3 Amgen Immuno-oncology Therapy Introduction
    • 11.1.4 Amgen Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.1.5 Amgen Recent Development
  • 11.2 AstraZeneca
    • 11.2.1 AstraZeneca Company Details
    • 11.2.2 AstraZeneca Business Overview
    • 11.2.3 AstraZeneca Immuno-oncology Therapy Introduction
    • 11.2.4 AstraZeneca Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.2.5 AstraZeneca Recent Development
  • 11.3 Bristol-Myers Squibb
    • 11.3.1 Bristol-Myers Squibb Company Details
    • 11.3.2 Bristol-Myers Squibb Business Overview
    • 11.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Introduction
    • 11.3.4 Bristol-Myers Squibb Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.3.5 Bristol-Myers Squibb Recent Development
  • 11.4 Eli-Lilly
    • 11.4.1 Eli-Lilly Company Details
    • 11.4.2 Eli-Lilly Business Overview
    • 11.4.3 Eli-Lilly Immuno-oncology Therapy Introduction
    • 11.4.4 Eli-Lilly Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.4.5 Eli-Lilly Recent Development
  • 11.5 Roche
    • 11.5.1 Roche Company Details
    • 11.5.2 Roche Business Overview
    • 11.5.3 Roche Immuno-oncology Therapy Introduction
    • 11.5.4 Roche Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.5.5 Roche Recent Development
  • 11.6 GlaxoSmithKline
    • 11.6.1 GlaxoSmithKline Company Details
    • 11.6.2 GlaxoSmithKline Business Overview
    • 11.6.3 GlaxoSmithKline Immuno-oncology Therapy Introduction
    • 11.6.4 GlaxoSmithKline Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.6.5 GlaxoSmithKline Recent Development
  • 11.7 Janssen Biotech
    • 11.7.1 Janssen Biotech Company Details
    • 11.7.2 Janssen Biotech Business Overview
    • 11.7.3 Janssen Biotech Immuno-oncology Therapy Introduction
    • 11.7.4 Janssen Biotech Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.7.5 Janssen Biotech Recent Development
  • 11.8 Merck
    • 11.8.1 Merck Company Details
    • 11.8.2 Merck Business Overview
    • 11.8.3 Merck Immuno-oncology Therapy Introduction
    • 11.8.4 Merck Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.8.5 Merck Recent Development
  • 11.9 Novartis
    • 11.9.1 Novartis Company Details
    • 11.9.2 Novartis Business Overview
    • 11.9.3 Novartis Immuno-oncology Therapy Introduction
    • 11.9.4 Novartis Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.9.5 Novartis Recent Development
  • 11.10 Pfizer
    • 11.10.1 Pfizer Company Details
    • 11.10.2 Pfizer Business Overview
    • 11.10.3 Pfizer Immuno-oncology Therapy Introduction
    • 11.10.4 Pfizer Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.10.5 Pfizer Recent Development
  • 11.11 Sanofi
    • 11.11.1 Sanofi Company Details
    • 11.11.2 Sanofi Business Overview
    • 11.11.3 Sanofi Immuno-oncology Therapy Introduction
    • 11.11.4 Sanofi Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.11.5 Sanofi Recent Development
  • 11.12 Spectrum Pharmaceuticals
    • 11.12.1 Spectrum Pharmaceuticals Company Details
    • 11.12.2 Spectrum Pharmaceuticals Business Overview
    • 11.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Introduction
    • 11.12.4 Spectrum Pharmaceuticals Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.12.5 Spectrum Pharmaceuticals Recent Development
  • 11.13 Takeda
    • 11.13.1 Takeda Company Details
    • 11.13.2 Takeda Business Overview
    • 11.13.3 Takeda Immuno-oncology Therapy Introduction
    • 11.13.4 Takeda Revenue in Immuno-oncology Therapy Business (2016-2021)
    • 11.13.5 Takeda Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Immuno-oncology Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immuno-oncology Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Monoclonal Antibodies
    Immune Checkpoint Inhibitors
    Immune System Modulators
    Cancer Vaccines
    Others

    Segment by Application
    Hospitals
    Ambulatory Surgical Center
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Amgen
    AstraZeneca
    Bristol-Myers Squibb
    Eli-Lilly
    Roche
    GlaxoSmithKline
    Janssen Biotech
    Merck
    Novartis
    Eli-Lilly
    Roche
    Spectrum Pharmaceuticals

    Buy now